AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

Amgen (AMGN) data supports long-term growth potential says analyst

November 8, 2022 10:37 AM EST

Amgen (NASDAQ: AMGN) reported new analysis from its Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha on Tuesday, stating that the data reinforces long-term efficacy and the consistent safety profile.

Amgen shares are up more than 5% following the... More

Amgen (AMGN) PT Raised to $325 at Jefferies Following AMG-133 Update

November 8, 2022 8:16 AM EST

Jefferies analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $325.00 (from $300.00) while maintaining a Buy rating.

The analyst commented, "AMGN update looks positive and consistent w/ our Buy, with valuation likely to go up with AMG-133 for obesity... More